Mayo Clinic, Rochester, MN
Joshua Pritchett, Jonas Paludo, Robert Haemmerle, Qian Shi, Nandita Khera, Zachary Yetmar, John W. Wilson, Rozalina McCoy, Angela Leuenberger, Sarah Phillips, Dominick Pahl, Sara M. Kloft-Nelson, Lindsey R. Sangaralingham, Alexander J. Ryu, David Phelan, Naseema Gangat, Julian R. Molina, Jon Charles Tilburt, Bijan J. Borah, Tufia C. Haddad
Background: The DEFeNDR (Decreasing the burden of Febrile Neutropenia through Dynamic RPM) program leverages in-home technology and centralized nurse monitoring to facilitate ambulatory management as an alternative to hospital-based care for cancer patients with neutropenic fever (NF). The objective of this study is to assess 30-day care utilization outcomes and patient satisfaction at 12 months after program implementation. Methods: Adult cancer patients hospitalized with NF were assessed daily for DEFeNDR program eligibility including MASCC score ≥21 (per ASCO guidelines) and no cellular therapy (CAR-T, BMT) in the prior 100 days. Patients agreeing to participate in the 30-day program received a cellular-enabled tablet with pre-connected devices for twice-daily vital signs and symptom assessments. Patient generated data were EHR-integrated in real-time. Embedded decision trees facilitated alerts for adverse trends. Virtual RPM nurses responded to alerts and utilized predefined care pathways. The primary endpoint was the mean proportion of evaluable days spent inpatient (mPEDI) within 30 days of eligibility comparing those who participated in the program (RPM) with those who declined (no RPM). Results: Of 85 eligible patients, 62 were offered DEFeNDR participation. Of those, 34 (54.8%) participated and 28 (45.2%) declined. Baseline characteristics and care utilization outcomes are summarized in Table 1. RPM patients experienced significantly lower mPEDI compared with unmonitored patients [5.1% (Standard Error [SE], 1.9%) vs 12.4% (SE, 2.1%); Wilcoxon Rank Sums p-value, 0.032]. RPM patients also experienced a trend toward fewer total hospital days and lower 30-day readmission rate, as well as shorter mean length of stay and lower rate of ICU utilization when readmitted. Non-visit care activities (EHR clinical communications, documentation, and patient messaging) were decreased from pre-hospital baseline for 58.8% of RPM patients versus 46.6% of those unmonitored. All RPM patients completing a patient satisfaction survey (n=9) indicated that they would recommend the program to patients with a similar condition. Conclusions: Cancer patients with NF participating in the DEFeNDR program experienced a significant reduction in mPEDI and care utilization compared with those who declined. Further studies are warranted to assess comparative effectiveness of this model vs usual care.
Baseline Characteristics | RPM | no RPM | 30-Day Care Utilization | RPM | no RPM | P-value |
---|---|---|---|---|---|---|
n | 34 | 28 | mPEDI | 5.1% | 12.4% | 0.032 |
Median Age, years (range) | 63 (24-83) | 60 (25-83) | Mean inpatient days | 1.4 | 3.3 | 0.053 |
% Female | 38% | 39% | Readmission rate | 29.4% | 42.9% | 0.271 |
Median MASCC score at admission (range) | 21 (13-26) | 20 (11-26) | Readmission: mean length of stay | 3.4 | 6.0 | 0.264 |
% with antibiotics continued at discharge | 61.8% | 57.1% | Readmission: ICU utilization rate | 10% | 33% | 0.323 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Joshua Pritchett
2022 ASCO Annual Meeting
First Author: Rayna Kuthiala
2023 ASCO Quality Care Symposium
First Author: AnnMarie Mazzella Ebstein
2021 ASCO Annual Meeting
First Author: Jordan Villars